IQVIA (IQV) Stock Forecast & Price Target

Q: What analysts cover IQVIA?

IQVIA has been rated by research analysts at Barclays , BMO Capital Markets , Deutsche Bank Aktiengesellschaft , HSBC , JPMorgan Chase & Co. , Mizuho , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and William Blair in the past 90 days.

$258.48 -2.24 (-0.86%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$257.79 -0.69 (-0.27%)

As of 10/2/2026 07:30 PM Eastern

Compare

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
3

Buy
14

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 3 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for IQV.

Consensus Price Target

$264.31
2.26% Upside

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $264.31. The highest price target for IQV is $345.00, while the lowest price target for IQV is $185.00. The average price target represents a forecasted upside of 2.26% from the current price of $258.48.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

Type	Current Forecast 10/4/25 to 10/4/26	1 Month Ago 9/4/25 to 9/4/26	3 Months Ago 7/6/25 to 7/6/26	1 Year Ago 10/4/24 to 10/4/25
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	17 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$264.31	$243.63	$222.00	$228.14
Forecasted Upside	2.26% Upside	-8.87% Downside	7.73% Upside	10.30% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Healthcare Companies	Broader Market
Consensus Rating Score	2.94	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	2.26% Upside	827.17% Upside	21.53% Upside
News Sentiment Rating	Positive News See Recent IQV News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/30/2026	UBS Group 4 of 5 stars	Kevin Caliendo 3 of 5 stars	Initiated Coverage	Buy	$345.00	+28.31%
9/29/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Boost Target	Outperform	$247.00 ➝ $319.00	+17.71%
9/28/2026	Truist Financial 3 of 5 stars	Jailendra Singh 1 of 5 stars	Reiterated Rating	Buy	$300.00 ➝ $329.00	+22.28%
9/24/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C) ➝ Hold (C+)
9/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$240.00 ➝ $270.00	-0.92%
7/29/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$233.00 ➝ $288.00	+16.49%
7/29/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean Dodge Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$210.00 ➝ $270.00	+8.48%
7/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$220.00 ➝ $276.00	+12.00%
7/29/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$225.00 ➝ $285.00	+15.65%
7/29/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$252.00 ➝ $287.00	+16.98%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
7/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$215.00 ➝ $230.00	+10.51%
7/9/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$240.00	+14.43%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$240.00	+16.25%
4/8/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$185.00	+10.93%
2/6/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$270.00 ➝ $255.00	+36.01%
2/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$230.00 ➝ $200.00	+6.68%
9/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$214.00	+17.92%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Garro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$280.00 ➝ $250.00	+20.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:06 PM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 3, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA Holdings Inc. recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, posting earnings per share of $3.15 against a consensus estimate of $3.03 and generating revenue of $4.37 billion, which exceeded the projected $4.30 billion. This consistent ability to outperform market forecasts, combined with a year-over-year revenue growth rate of 8.7%, signals robust operational execution and demand for the company's life sciences services.
The stock has attracted significant institutional support, highlighted by UBS Group upgrading IQVIA Holdings Inc. to a "Strong-Buy" rating and Royal Bank of Canada raising its price target to $319.00. These recent analyst actions, which suggest a potential upside of over 23% from the current level, reflect growing confidence in the company's long-term growth trajectory and its position as a leader in healthcare analytics and clinical research.
IQVIA Holdings Inc. is currently trading at $258.48, a price point that remains well below its 52-week high of $277.40 and significantly above its 52-week low of $154.50. This positioning indicates that the stock has experienced substantial appreciation over the past year, suggesting that the market is increasingly valuing the company's strategic initiatives and its role in the evolving healthcare technology landscape.
The company has set ambitious full-year 2026 guidance, projecting earnings per share between $12.80 and $13.00, which is higher than the consensus estimate of $12.57. This upward revision in guidance, coupled with revenue guidance of $17.3 billion to $17.5 billion, demonstrates management's confidence in sustaining growth momentum and delivering value to shareholders through its Technology & Analytics and Research & Development segments.
IQVIA Holdings Inc. benefits from a favorable industry tailwind as new drug approvals accelerate, a trend noted by RBC Capital Markets as a "meaningful" driver for the company. As a global provider of clinical research services and healthcare intelligence, the company is well-positioned to capture increased spending from pharmaceutical and biotechnology clients who are ramping up their development pipelines and commercialization efforts.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

The company carries a significant debt burden, with a debt-to-equity ratio of 2.18 and net debt reported at approximately $14.1 billion. This high leverage level can limit financial flexibility and increase interest expenses, potentially pressuring margins and reducing the company's ability to invest in growth initiatives or return capital to shareholders during periods of economic uncertainty.
Recent insider activity has been predominantly negative, with multiple executives selling shares in the past few months. For instance, Eric Sherbet sold 5,000 shares and James G. Berkshire sold 2,668 shares in late 2026. While insider sales can be attributed to personal financial planning, a consistent pattern of selling may signal that company insiders perceive the stock as overvalued or are reducing their personal exposure to the company's equity.
IQVIA Holdings Inc. does not currently pay a dividend, as indicated by a dividend yield of 0.00%. For income-focused investors, this lack of cash flow distribution means that returns are entirely dependent on capital appreciation. In a volatile market environment, the absence of a dividend cushion can make the stock more susceptible to price declines without the offsetting benefit of regular income payments.
The stock exhibits higher volatility than the broader market, with a beta of 1.17. This means that IQVIA Holdings Inc. shares are expected to be 17% more volatile than the S&P 500 index. Investors with lower risk tolerance may find this level of price fluctuation challenging, as the stock can experience sharper declines during market downturns compared to less volatile peers.
Despite strong growth, the company's valuation remains elevated, with a P/E ratio of 22.73 and a PEG ratio of 2.30. These metrics suggest that the stock is priced for continued high growth, leaving little room for error. If future earnings growth slows or fails to meet the high expectations set by recent guidance, the stock could face significant downward pressure as investors reassess its valuation.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $264.31, with a high forecast of $345.00 and a low forecast of $185.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 2.26% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 4 upgrades by analysts.

IQVIA has been rated by research analysts at Barclays, BMO Capital Markets, Deutsche Bank Aktiengesellschaft, HSBC, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and William Blair in the past 90 days.

Analysts like IQVIA more than other "healthcare" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

MarketBeat monitors more than a dozen sources for IQVIA analyst ratings, with the most recent rating issued on 9/30/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target